ABR--Affinity BioReagents, Inc. manufactures and distributes monoclonal and polyclonal antibodies, and recombinant proteins for the scientific research community. The company offers cell biology products that include apoptosis, cell adhesion and junctions, structure markers, and cytokines; cell signaling products, such as bioactive peptides, G protein-coupled receptors, kinases, membrane receptors, steroid receptors, and steroids hormones; controls, secondaries, and tags that include blocking peptides and secondary antibodies; and muscle biology, nuclear biology, neurobiology, and stem cell biology products. It also provides reagents and immunology services. ABR--Affinity BioReagents, Inc. markets its products through a network of distribution partners in Australia, Austria, Bahrain, Belgium, Brazil, Canada, Chile, China, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Kuwait, Latin America, Latvia, Lithuania, Luxembourg, Malaysia, Mercosur, Mexico, the Netherlands, New Zealand, Norway, Poland, Portugal, the Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, the United Arab Emirates, the United Kingdom, the United States, and Vietnam. The company was founded in 1989 and is based in Golden, Colorado. ABR--Affinity BioReagents, Inc. operates as a subsidiary of Pierce Biotechnology Inc.